Skip to main content
OpenTrials
Completed

NCT Number: NCT03646331

Bioequivalence of Imeglimin Tablet Formulations

This is an open-label assessment of the bioequivalence of two 500 mg-tablet formulations of imeglimin (Tablet A [reference product] and Tablet B [test product]), in at least 16 healthy Caucasian volunteers.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Hammersmith Medicines Research (HMR)

London, United Kingdom

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • BMI : 18.5-29.9
  • Body weight ≥ 60 kg
  • willing to use reliable contraception
  • able to give fully informed written consent.

Exclusion criteria

  • Positive tests for hepatitis B & C, HIV
  • severe adverse reaction to any drug; sensitivity to trial medication and/or food allergies
  • drug or alcohol abuse
  • smoking of more than 5 cigarettes daily or drinking more than 5 cups of caffeinated drinks daily
  • over-the-counter medication, vitamins and herbal remedies, or prescribed medication in the 20 days before the first dose of trial medication (with the exception of paracetamol [acetaminophen] and oral contraception);
  • participation in other clinical trials of unlicensed medicines, or loss of more than 400 mL blood, within the previous 3 months
  • vital signs outside the acceptable range
  • clinically relevant abnormal findings at the screening assessment; estimated glomerular filtration rate (eGFR) at screening < 80 mL/min/1.73 m2
  • acute or chronic illness
  • clinically relevant abnormal medical history or concurrent medical condition;
  • surgery or medical condition that might affect the absorption of medicines;
  • possibility that volunteer will not cooperate
  • pre-menopausal females who are pregnant or lactating, or who are sexually active and not using a reliable method of contraception;
  • objection by the volunteer's General Practitioner (GP).

Treatment and study plan

Imeglimin Reference product

Drug

Reference product

Imeglimin

Drug

Test product (new formulation tablet)

Primary outcomes

  1. Pk parameters of imeglimin

    Time frame: from dosing up to 48h

    Cmax: peak plasma concentration after dosing

Secondary outcomes

  1. PK parameters of Imeglimin

    Time frame: from dosing up to 48h

    AUC last: area Under the concentration time curve

  2. Incidence of treatment emergent adverse events (Safety and tolerability)

    Time frame: From Day 1 to Day 15

    Incidence of treatment emergent adverse events

Sponsors and collaborators

Lead sponsor

Poxel SA

Industry

Registry information

Official study title

A Phase I, Open-label, Randomised, Single-centre, 2-way Crossover Bioequivalence Study Comparing 2 Formulations of Imeglimin After Single Oral Doses in Healthy Caucasian Subjects

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
Aug 24, 2018
Registry last updated
Jan 11, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.